C-S5SWShip of Theseus
HOX biologics, degradation resistance, transcription factors
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-S5SW
C-S5SWC-S5SWHOX biologics, degradation resistance, transcription factors
0-100 chain-logic scale · 15 dimensions · scored on public evidence
On the archived homepage, Ship of Theseus presents itself simply as "a bioengineering company," indicating a broad commitment to bioengineering but no more specific mission, ideology, mechanism, or longevity theory is visible in the provided snapshot text.
SourceShip of Theseus presents the view that HOX family proteins can be turned into useful therapeutics by engineering them to resist degradation. The company states that its proprietary HOX+ biologics modify the degron region of HOX molecules to extend intracellular half-life, based on the idea that HOX genes are master regulators of many context-specific cell phenotypes and that longer-lasting HOX proteins could improve their therapeutic utility.
SourceShip of Theseus states that HOX family transcription factors are powerful master regulators of context-specific cell phenotypes and can be turned into disease-modifying therapeutics by modifying their conserved degron region to resist intracellular degradation. The company further indicates that combining these longer-lived HOX+ proteins with cell-penetrating and nuclear-targeting peptide motifs enables rapid cellular entry, multi-day persistence, reduced dosing burden, and in situ clinical use rather than specialized ex vivo culture.
SourceShip of Theseus presents the view that modifying HOX family proteins to resist intracellular degradation can make them practical and effective therapeutics. The company states that HOX genes are master regulators of context-specific cell phenotypes, and that its proprietary HOX+ proteins, altered at the degron region, can enter cells quickly and persist for days rather than minutes, enabling lower dosing, lower culture cost, easier shipping, and faster clinical translation across applications such as wound healing, stem cell expansion, infertility, and chemotherapy-induced alopecia.
SourceShip of Theseus presents the view that HOX family transcription factors can be turned into disease-modifying therapeutics by engineering them to resist intracellular degradation and by adding cell-penetrating and nuclear-targeting motifs. The company states that because HOX genes are master regulators of context-specific cell phenotypes, stabilized HOX+ proteins can act inside cells for days instead of minutes, enabling lower-dose, less frequent, and more practical therapeutic use.
Source